Results
1 -
10 of
33T. M. A. Eldebss, S. M. Gomha, M. M. Abdulla, R. K. Arafa.
5 Antineoplastics, Reactions Weekly New Indole-Containing Medicinal Compounds, Heterocyclic Scaffolds II: A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma, Cancer Chemotherapy and Pharmacology Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo, BMC Cancer Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology Pathological animal models in the experimental evaluation of tumournmicrovasculature with magnetic resonance imaging, La radiologia medica SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression, Cancer Cell International Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors, Cancer Chemotherapy and Pharmacology